Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker-Driven Pharmacological Treatment for Autism Spectrum Disorder
NCT05063656Phase 4Completed
- Start
- Feb 2022
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of gabapentin in Autism Spectrum Disorder (ASD). Started Feb 2022; status: completed.
02
Drugs
gabapentin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT05063656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063656.